Temporal evolution of myeloperoxidase and galectin 3 during 1 year after acute coronary syndrome admission - 07/11/19
Doi : 10.1016/j.ahj.2019.02.016
Maxime M. Vroegindewey, MSc a, k, Victor J. van den Berg, MD, MSc a, b, k, Elke Bouwens, MD, MSc a, K. Martijn Akkerhuis, MD, PhD a, Rohit M. Oemrawsingh, MD, MSc a, c, Folkert W Asselbergs, MD, PhD d, Timo Lenderink, MD, PhD e, Pim van der Harst, MD, PhD f, Eelco Ronner, MD, PhD g, Victor A.W.M. Umans, MD, PhD b, Isabella Kardys, MD, PhD a, Eric Boersma, PhD a, ⁎ 
a Erasmus MC, University Medical Center Rotterdam, Thoraxcenter, Department of Cardiology, Rotterdam, The Netherlands
b Department of Cardiology, Northwest Clinics, Alkmaar, The Netherlands
c Department of Cardiology, Amphia Hospital, Breda, The Netherlands
d Department of Cardiology, Division Heart & Lungs, University Medical Centre Utrecht, University of Utrecht, The Netherlands
e Zuyderland Hospital, Heerlen, The Netherlands
f University Medical Centre Groningen, Groningen, The Netherlands
g Reinier de Graaf Hospital, Delft, The Netherlands
∗Reprint requests: Prof. Eric Boersma, PhD, MSc, FESC, Erasmus MC, Department of Cardiology, room Na317, PO Box 2040, 3000, CA, Rotterdam, The Netherlands.Erasmus MCDepartment of Cardiologyroom Na317PO Box 2040RotterdamCA3000The Netherlands
Rotterdam, Alkmaar, Breda, Utrecht, Heerlen, Groningen, and Delft, The Netherlands
Abstract |
Prior studies reported that Myeloperoxidase and Galectin-3, which are biomarkers of coronary plaque vulnerability, are elevated in acute coronary syndrome (ACS) patients. We studied the temporal evolution of these biomarkers early after ACS admission and prior to a recurrent ACS event during 1 year follow-up.
Le texte complet de cet article est disponible en PDF.Plan
| Declaration of interest statement: This work was supported by the Dutch Heart Foundation (grant number 2007B012), the Netherlands Heart Institute-Interuniversity Cardiology Institute of the Netherlands (project number 071.01) and the Working Group on Cardiovascular Research Netherlands, all of which are non-commercial funding bodies. An unrestricted research grant was further obtained from Eli Lilly, the Netherlands. |
|
| Disclosures: None. |
© 2019
Elsevier Inc. Tous droits réservés.
Vol 216
P. 143-146 - octobre 2019 Retour au numéro
Article précédent
- High prevalence of cholesterol-rich atherosclerotic lesions in ancient mummies: A near-infrared spectroscopy study
- Mohammad Madjid, Payam Safavi-Naeini, Robert Lodder
- Clinical effects of cyclosporine in acute anterior myocardial infarction complicated by heart failure: A subgroup analysis of the CIRCUS Trial
- Marc J Claeys, Patrick Coussement, Philippe Dubois, D. Garcia-Dorado, N. Mewton, C Amaz, M. Ovize
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?